The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases

Thomas Zilli; Piet Dirix; Reino Heikkilä; Nick Liefhooghe; Shankar Siva; Alfonso Gomez-Iturriaga; Wouter Everaerts; François Otte; Mohamed Shelan; Carole Mercier; Vérane Achard; Kristian Thon; Karin Stellamans; Daniel Moon; Antonio Conde-Moreno; Alexandros Papachristofilou; Marta Scorsetti; Matthias Gückenberger; Filip Ameye; Almudena Zapatero; Lien Van De Voorde; Fernando López Campos; Felipe Couñago; Maud Jaccard; An Spiessens; Isabelle Semac; Frederik Vanhoutte; Els Goetghebeur; Dries Reynders; Piet Ost

doi:10.1016/j.euf.2020.12.010

The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases

Eur Urol Focus. 2021 Mar;7(2):241-244. doi: 10.1016/j.euf.2020.12.010. Epub 2020 Dec 29.

Authors

Thomas Zilli¹, Piet Dirix², Reino Heikkilä³, Nick Liefhooghe⁴, Shankar Siva⁵, Alfonso Gomez-Iturriaga⁶, Wouter Everaerts⁷, François Otte⁸, Mohamed Shelan⁹, Carole Mercier², Vérane Achard¹⁰, Kristian Thon³, Karin Stellamans⁴, Daniel Moon¹¹, Antonio Conde-Moreno¹², Alexandros Papachristofilou¹³, Marta Scorsetti¹⁴, Matthias Gückenberger¹⁵, Filip Ameye¹⁶, Almudena Zapatero¹⁷, Lien Van De Voorde¹⁸, Fernando López Campos¹⁹, Felipe Couñago²⁰, Maud Jaccard¹⁰, An Spiessens²¹, Isabelle Semac¹⁰, Frederik Vanhoutte²¹, Els Goetghebeur²², Dries Reynders²², Piet Ost²³

Affiliations

¹ Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland. Electronic address: thomas.zilli@hcuge.ch.
² Department of Radiation Oncology, Iridium Kankernetwerk, Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium.
³ Department of Oncology, Oslo University Hospital, Oslo, Norway.
⁴ Department of Radiation Oncology, AZ Groeninge, Kortrijk, Belgium.
⁵ Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
⁶ Biocruces Health Research Institute, Cruces University Hospital, Barakaldo, Spain.
⁷ Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
⁸ Department of Radiation Oncology, Jules Bordet Institute and Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium.
⁹ Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
¹⁰ Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.
¹¹ Royal Melbourne Clinical School, University of Melbourne, Melbourne, Australia.
¹² Department of Radiation Oncology, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
¹³ Department of Radiotherapy and Radiation Oncology, University Hospital Basel, Basel, Switzerland.
¹⁴ Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Hospital IRCSS, Rozzano, Italy.
¹⁵ Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
¹⁶ Department of Urology, AZ Maria-Middelares, Ghent, Belgium.
¹⁷ Department of Radiation Oncology, University Hospital La Princesa, Madrid, Spain.
¹⁸ Department of Radiation Oncology, AZ St-Lucas, Ghent, Belgium.
¹⁹ Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
²⁰ Department of Radiation Oncology, University Hospital Quironsalud, Universidad Europea de Madrid, Madrid, Spain.
²¹ Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium.
²² Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.
²³ Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium. Electronic address: piet.ost@ugent.be.

PMID: 33386290
DOI: 10.1016/j.euf.2020.12.010

Abstract

Optimal local treatment for nodal oligorecurrent prostate cancer is unknown. The randomized phase 2 PEACE V-STORM trial will explore the best treatment approach in this setting. Early results on the acute toxicity profile are projected to be published in quarter 3, 2021.

Trial registration: ClinicalTrials.gov NCT03569241.

Publication types

Clinical Trial, Phase II
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Male
Prostatic Neoplasms* / therapy
Salvage Therapy*

Associated data

ClinicalTrials.gov/NCT03569241